Details of the Drug

General Information of Drug (ID: DMRQD04)

• Drug Name: Tramadol
• Synonyms: Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram

Indication

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Approved	[1]
Pain	MG30-MG3Z	Approved	[2]
Chronic pain	MG30	Investigative	[1]
Premature ejaculation	HA03.0Z	Investigative	[1]

• Therapeutic Class: Analgesics
• Affected Organisms: Humans and other mammals
• ATC Code:
  N02AX02: Tramadol
  N02AX: Other opioids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02AX02: Tramadol
  N02AX: Other opioids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02AX02: Tramadol
  N02AX: Other opioids
  N02A: OPIOIDS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 263.37
  Logarithm of the Partition Coefficient (xlogp); 2.6
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 300 mcg/L []
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.6-1.9 h []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 75% []
  Clearance: The clearance of drug is 3.73 mL/min/kg in renal impairment patients [4]
  Elimination: Tramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys, accounting for 90% of the excretion while the remaining 10% is excreted through feces [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 6 hours [6]
  Metabolism: The drug is metabolized via the liver [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.271 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.8% [9]
  Vd: The volume of distribution (Vd) of drug is 2.6-2.9 L/kg [10]
• Chemical Identifiers:
  Formula: C16H25NO2
  IUPAC Name: (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
  Canonical SMILES: CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
  InChI: InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
  InChIKey: TVYLLZQTGLZFBW-ZBFHGGJFSA-N
• Cross-matching ID:
  PubChem CID: 33741
  ChEBI ID: CHEBI:75725
  CAS Number: 123154-38-1
  UNII: 39J1LGJ30J
  DrugBank ID: DB00193
  TTD ID: D05GKD
  VARIDT ID: DR00088
  INTEDE ID: DR1627
  ACDINA ID: D00693
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Modulator	[11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[14]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[15]
Creatine kinase B-type (CKB)	OTUCKOTT	KCRB_HUMAN	Gene/Protein Processing	[15]
kinase isozyme 3, mitochondrial (PDK3)	OTCPSTID	PDK3_HUMAN	Gene/Protein Processing	[15]
L-lactate dehydrogenase A chain (LDHA)	OTN7K4XB	LDHA_HUMAN	Gene/Protein Processing	[15]
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (NDUFS1)	OTTIZDFR	NDUS1_HUMAN	Gene/Protein Processing	[15]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Gene/Protein Processing	[16]

Molecular Expression Atlas of This Drug

• The Studied Disease: Osteoarthritis
• ICD Disease Classification: FA00-FA05

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
5-HT 2C receptor (HTR2C)	DTT	HTR2C	1.02E-02	-0.45	-0.37
5-HT 2C receptor (HTR2C)	DTT	HTR2C	2.27E-01	0.27	0.6
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.19E-01	-1.32E-01	-2.77E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.65E-01	-1.47E-01	-4.48E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	8.03E-01	9.92E-03	4.89E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.42E-01	-4.97E-02	-3.73E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	9.90E-01	3.10E-03	1.75E-02
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	5.35E-01	1.10E-02	1.19E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.59E-01	6.29E-02	3.14E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	4.84E-01	-8.38E-02	-8.46E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tramadol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Tramadol and Dextropropoxyphene.	Pain [MG30-MG3Z]	[17]
Oxymorphone	DM65AGJ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Oxymorphone.	Pain [MG30-MG3Z]	[18]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Tramadol and Levorphanol.	Pain [MG30-MG3Z]	[18]
Hydromorphone	DMHP21E	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Hydromorphone.	Pain [MG30-MG3Z]	[18]
Codeine	DMJX6ZG	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Codeine.	Pain [MG30-MG3Z]	[18]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Tramadol and Flavoxate.	Pain [MG30-MG3Z]	[19]
Methamphetamine	DMPM4SK	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Methamphetamine.	Pain [MG30-MG3Z]	[18]
Hydrocodone	DMQ2JO5	Major	Additive hypotensive effects by the combination of Tramadol and Hydrocodone.	Pain [MG30-MG3Z]	[18]
Meperidine	DMX4GND	Major	Additive hypotensive effects by the combination of Tramadol and Meperidine.	Pain [MG30-MG3Z]	[18]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Tramadol and Oxycodone.	Pain [MG30-MG3Z]	[18]

Coadministration of a Drug Treating the Disease Different from Tramadol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Bethanechol.	Abnormal micturition [MF50]	[18]
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Tramadol and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[20]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Tramadol and Ivosidenib.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Midostaurin.	Acute myeloid leukaemia [2A60]	[22]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Idarubicin.	Acute myeloid leukaemia [2A60]	[22]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Daunorubicin.	Acute myeloid leukaemia [2A60]	[22]
Arn-509	DMT81LZ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Arn-509.	Acute myeloid leukaemia [2A60]	[18]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Gilteritinib.	Acute myeloid leukaemia [2A60]	[23]
Oliceridine	DM6MDCF	Major	Additive hypotensive effects by the combination of Tramadol and Oliceridine.	Acute pain [MG31]	[18]
Chlorzoxazone	DMCYVDT	Major	Additive CNS depression effects by the combination of Tramadol and Chlorzoxazone.	Acute pain [MG31]	[24]
Scopolamine	DMOM8AL	Moderate	Additive antimotility effects by the combination of Tramadol and Scopolamine.	Addictive disorder [6C50-6C5Z]	[19]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Tacrine	DM51FY6	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Tacrine.	Alzheimer disease [8A20]	[18]
Galantamine	DMEO794	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Galantamine.	Alzheimer disease [8A20]	[18]
Rivastigmine	DMG629M	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Rivastigmine.	Alzheimer disease [8A20]	[18]
Donepezil	DMIYG7Z	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Donepezil.	Alzheimer disease [8A20]	[18]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Tramadol and Metronidazole.	Amoebiasis [1A36]	[25]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Tramadol and Ivabradine.	Angina pectoris [BA40]	[26]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Tramadol and Bepridil.	Angina pectoris [BA40]	[22]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Tramadol and Dronedarone.	Angina pectoris [BA40]	[22]
Marinol	DM70IK5	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Marinol.	Anorexia nervosa [6B80]	[18]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Tramadol and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[27]
Butalbital	DM9J04X	Major	Additive CNS depression effects by the combination of Tramadol and Butalbital.	Anxiety disorder [6B00-6B0Z]	[24]
Buspirone	DMBS632	Major	Additive CNS depression effects by the combination of Tramadol and Buspirone.	Anxiety disorder [6B00-6B0Z]	[28]
Clorazepate	DMC3JST	Major	Additive CNS depression effects by the combination of Tramadol and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[29]
Alprazolam	DMC7XDN	Major	Additive CNS depression effects by the combination of Tramadol and Alprazolam.	Anxiety disorder [6B00-6B0Z]	[24]
Methylphenobarbital	DMDSWAG	Major	Additive CNS depression effects by the combination of Tramadol and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[29]
Hydroxyzine	DMF8Y74	Major	Additive CNS depression effects by the combination of Tramadol and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[24]
Halazepam	DMPFWO6	Major	Additive CNS depression effects by the combination of Tramadol and Halazepam.	Anxiety disorder [6B00-6B0Z]	[24]
Chlordiazepoxide	DMTN5XI	Major	Additive CNS depression effects by the combination of Tramadol and Chlordiazepoxide.	Anxiety disorder [6B00-6B0Z]	[24]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Tramadol and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[24]
Clobazam - Lundbeck	DMW1OQ0	Major	Additive CNS depression effects by the combination of Tramadol and Clobazam - Lundbeck.	Anxiety disorder [6B00-6B0Z]	[24]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Tramadol and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[24]
Promazine	DMZAL7W	Major	Additive CNS depression effects by the combination of Tramadol and Promazine.	Appearance/behaviour symptom [MB23]	[24]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Cilostazol.	Arterial occlusive disease [BD40]	[22]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Posaconazole.	Aspergillosis [1F20]	[22]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Levalbuterol.	Asthma [CA23]	[30]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Terbutaline.	Asthma [CA23]	[31]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Pirbuterol.	Asthma [CA23]	[31]
Isoetharine	DMITSEH	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Isoetharine.	Asthma [CA23]	[31]
Aminophylline	DML2NIB	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Aminophylline.	Asthma [CA23]	[18]
Ephedrine	DMMV0KW	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Ephedrine.	Asthma [CA23]	[18]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Salbutamol.	Asthma [CA23]	[30]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Formoterol.	Asthma [CA23]	[31]
Atomoxetine	DM5L6HI	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[22]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[18]
Methylphenidate	DM7SJD6	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Methylphenidate.	Attention deficit hyperactivity disorder [6A05]	[18]
Desipramine	DMT2FDC	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[18]
Ofloxacin	DM0VQN3	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[18]
Erythromycin	DM4K7GQ	Moderate	Decreased metabolism of Tramadol caused by Erythromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[22]
Ertapenem	DM4S3O8	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Ertapenem.	Bacterial infection [1A00-1C4Z]	[18]
Meropenem	DM62UHC	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Meropenem.	Bacterial infection [1A00-1C4Z]	[18]
Trovafloxacin	DM6AN32	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Tramadol and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Tramadol and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Tramadol and Linezolid.	Bacterial infection [1A00-1C4Z]	[33]
Gemifloxacin	DMHT34O	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Imipenem	DMI9FBP	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Imipenem.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
ABT-492	DMJFD2I	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and ABT-492.	Bacterial infection [1A00-1C4Z]	[18]
Levofloxacin	DMS60RB	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Moxifloxacin	DMU8V4S	Major	Increased risk of prolong QT interval by the combination of Tramadol and Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[34]
Lomefloxacin	DMVRH9C	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Telithromycin.	Bacterial infection [1A00-1C4Z]	[22]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Retigabine.	Behcet disease [4A62]	[22]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Tramadol and Cariprazine.	Bipolar disorder [6A60]	[24]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Loperamide.	Bowel habit change [ME05]	[35]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Eribulin.	Breast cancer [2C60-2C6Y]	[22]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Lapatinib.	Breast cancer [2C60-2C6Y]	[22]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Tamoxifen.	Breast cancer [2C60-2C6Y]	[22]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Tramadol and Toremifene.	Breast cancer [2C60-2C6Y]	[22]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Bosutinib.	Breast cancer [2C60-2C6Y]	[26]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Tramadol and Grepafloxacin.	Bronchitis [CA20]	[32]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Tramadol and Sotalol.	Cardiac arrhythmia [BC9Z]	[22]
Dofetilide	DMPN1TW	Major	Increased risk of prolong QT interval by the combination of Tramadol and Dofetilide.	Cardiac arrhythmia [BC9Z]	[22]
Secobarbital	DM14RF5	Major	Additive CNS depression effects by the combination of Tramadol and Secobarbital.	Chronic insomnia [7A00]	[24]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[36]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Pregabalin	DMDVP3B	Major	Additive CNS depression effects by the combination of Tramadol and Pregabalin.	Chronic obstructive pulmonary disease [CA22]	[37]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Tramadol and Dihydrocodeine.	Chronic pain [MG30]	[17]
Morphine	DMRMS0L	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Morphine.	Chronic pain [MG30]	[18]
Levomilnacipran	DMV26S8	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Levomilnacipran.	Chronic pain [MG30]	[33]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Oxaliplatin.	Colorectal cancer [2B91]	[22]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Isoproterenol.	Conduction disorder [BC63]	[30]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Tramadol and Olopatadine.	Conjunctiva disorder [9A60]	[38]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Halothane.	Corneal disease [9A76-9A78]	[22]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Tramadol and Propofol.	Corneal disease [9A76-9A78]	[39]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Sevoflurane.	Corneal disease [9A76-9A78]	[22]
Lidocaine	DML4ZOT	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Lidocaine.	Corneal disease [9A76-9A78]	[18]
Cocaine	DMSOX7I	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Cocaine.	Corneal disease [9A76-9A78]	[40]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Tramadol and Alfentanil.	Corneal disease [9A76-9A78]	[18]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Tramadol and Remifentanil.	Corneal disease [9A76-9A78]	[18]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Probucol.	Coronary atherosclerosis [BA80]	[22]
Oxtriphylline	DMLHSE3	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Oxtriphylline.	Cough [MD12]	[18]
Methadone	DMTW6IU	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Methadone.	Cough [MD12]	[22]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Clofazimine.	Crohn disease [DD70]	[41]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Tramadol and Mifepristone.	Cushing syndrome [5A70]	[22]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Tramadol and Pasireotide.	Cushing syndrome [5A70]	[22]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Osilodrostat.	Cushing syndrome [5A70]	[26]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Tramadol and Ethanol.	Cystitis [GC00]	[38]
Sertraline	DM0FB1J	Major	Decreased metabolism of Tramadol caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[42]
Trimipramine	DM1SC8M	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Trimipramine.	Depression [6A70-6A7Z]	[18]
Imipramine	DM2NUH3	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Imipramine.	Depression [6A70-6A7Z]	[18]
Fluoxetine	DM3PD2C	Major	Additive serotonergic effects by the combination of Tramadol and Fluoxetine.	Depression [6A70-6A7Z]	[42]
Nortriptyline	DM4KDYJ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Nortriptyline.	Depression [6A70-6A7Z]	[18]
Vilazodone	DM4LECQ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Vilazodone.	Depression [6A70-6A7Z]	[33]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Tramadol and Nefazodone.	Depression [6A70-6A7Z]	[33]
Paroxetine	DM5PVQE	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Paroxetine.	Depression [6A70-6A7Z]	[42]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Tramadol and Selegiline.	Depression [6A70-6A7Z]	[33]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Tramadol and Vortioxetine.	Depression [6A70-6A7Z]	[42]
Duloxetine	DM9BI7M	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Duloxetine.	Depression [6A70-6A7Z]	[33]
Isocarboxazid	DMAF1NB	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Isocarboxazid.	Depression [6A70-6A7Z]	[33]
Milnacipran	DMBFE74	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Milnacipran.	Depression [6A70-6A7Z]	[25]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Tramadol and Escitalopram.	Depression [6A70-6A7Z]	[43]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Tramadol and Tranylcypromine.	Depression [6A70-6A7Z]	[33]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Tramadol and Desvenlafaxine.	Depression [6A70-6A7Z]	[33]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Tramadol and OPC-34712.	Depression [6A70-6A7Z]	[24]
Phenelzine	DMHIDUE	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Phenelzine.	Depression [6A70-6A7Z]	[33]
Clomipramine	DMINRKW	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Clomipramine.	Depression [6A70-6A7Z]	[18]
Trazodone	DMK1GBJ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Trazodone.	Depression [6A70-6A7Z]	[33]
Amitriptyline	DMK7F9S	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Amitriptyline.	Depression [6A70-6A7Z]	[18]
Amoxapine	DMKITQE	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Amoxapine.	Depression [6A70-6A7Z]	[18]
Mirtazapine	DML53ZJ	Major	Additive serotonergic effects by the combination of Tramadol and Mirtazapine.	Depression [6A70-6A7Z]	[33]
Protriptyline	DMNHTZI	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Protriptyline.	Depression [6A70-6A7Z]	[18]
Doxepin	DMPI98T	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Doxepin.	Depression [6A70-6A7Z]	[18]
Maprotiline	DMPWB7T	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Maprotiline.	Depression [6A70-6A7Z]	[18]
Venlafaxine	DMR6QH0	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Venlafaxine.	Depression [6A70-6A7Z]	[33]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Tramadol and Esketamine.	Depression [6A70-6A7Z]	[25]
Hyoscyamine	DM804UR	Moderate	Additive antimotility effects by the combination of Tramadol and Hyoscyamine.	Digestive system disease [DE2Z]	[19]
Mepenzolate	DM8YU2F	Moderate	Additive antimotility effects by the combination of Tramadol and Mepenzolate.	Digestive system disease [DE2Z]	[19]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Tramadol and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[44]
Oxybutynine	DMJPBAX	Moderate	Additive antimotility effects by the combination of Tramadol and Oxybutynine.	Discovery agent [N.A.]	[19]
PMID28870136-Compound-48	DMPIM9L	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and PMID28870136-Compound-48.	Discovery agent [N.A.]	[18]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Tramadol and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[17]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[22]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Tramadol and Deutetrabenazine.	Dystonic disorder [8A02]	[45]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Ingrezza.	Dystonic disorder [8A02]	[46]
Piperazine	DMTY9LU	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Piperazine.	Enterobiasis [1F65]	[18]
Fenfluramine	DM0762O	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[33]
Diazepam	DM08E9O	Major	Additive CNS depression effects by the combination of Tramadol and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[24]
Primidone	DM0WX6I	Major	Additive CNS depression effects by the combination of Tramadol and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[24]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Tramadol and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[37]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Tramadol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[47]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Tramadol and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[24]
Phenobarbital	DMXZOCG	Major	Additive CNS depression effects by the combination of Tramadol and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[24]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Tramadol caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Tramadol and Dantrolene.	Fever [MG26]	[24]
Solifenacin	DMG592Q	Moderate	Additive antimotility effects by the combination of Tramadol and Solifenacin.	Functional bladder disorder [GC50]	[19]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Tramadol caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[48]
Tolterodine	DMSHPW8	Moderate	Additive antimotility effects by the combination of Tramadol and Tolterodine.	Functional bladder disorder [GC50]	[19]
Darifenacin	DMWXLYZ	Moderate	Additive antimotility effects by the combination of Tramadol and Darifenacin.	Functional bladder disorder [GC50]	[19]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Pentamidine.	Fungal infection [1F29-1F2F]	[22]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Tramadol caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[49]
Fluconazole	DMOWZ6B	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Fluconazole.	Fungal infection [1F29-1F2F]	[22]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Tramadol caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[22]
Propantheline	DM2EN6G	Moderate	Additive antimotility effects by the combination of Tramadol and Propantheline.	Gastric ulcer [DA60]	[19]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Tramadol and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[22]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[22]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Tramadol and Brimonidine.	Glaucoma [9C61]	[50]
Cycloserine	DMT1I52	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Cycloserine.	HIV-infected patients with tuberculosis [1B10-1B14]	[18]
Procarbazine	DMIK367	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Procarbazine.	Hodgkin lymphoma [2B30]	[33]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Tramadol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Tramadol and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Tramadol and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Tramadol caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Tramadol caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[25]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Tramadol caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[56]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Tramadol and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[19]
Rimantadine	DM5DWMU	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Rimantadine.	Influenza [1E30-1E32]	[18]
Amantadine	DMS3YE9	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Amantadine.	Influenza [1E30-1E32]	[18]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tramadol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[57]
Temazepam	DM02A65	Major	Additive CNS depression effects by the combination of Tramadol and Temazepam.	Insomnia [7A00-7A0Z]	[24]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Tramadol and Suvorexant.	Insomnia [7A00-7A0Z]	[24]
Amobarbital	DM0GQ8N	Major	Additive CNS depression effects by the combination of Tramadol and Amobarbital.	Insomnia [7A00-7A0Z]	[24]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Tramadol and Ramelteon.	Insomnia [7A00-7A0Z]	[24]
Eszopiclone	DM8RZ9H	Major	Additive CNS depression effects by the combination of Tramadol and Eszopiclone.	Insomnia [7A00-7A0Z]	[24]
Flurazepam	DMAL4G0	Major	Additive CNS depression effects by the combination of Tramadol and Flurazepam.	Insomnia [7A00-7A0Z]	[24]
Butabarbital	DMC5AST	Major	Additive CNS depression effects by the combination of Tramadol and Butabarbital.	Insomnia [7A00-7A0Z]	[24]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Tramadol and Triazolam.	Insomnia [7A00-7A0Z]	[24]
Pentobarbital	DMFNH7L	Major	Additive CNS depression effects by the combination of Tramadol and Pentobarbital.	Insomnia [7A00-7A0Z]	[24]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Tramadol and Zaleplon.	Insomnia [7A00-7A0Z]	[24]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Tramadol and Propiomazine.	Insomnia [7A00-7A0Z]	[24]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Tramadol and Tasimelteon.	Insomnia [7A00-7A0Z]	[24]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Tramadol and Paraldehyde.	Insomnia [7A00-7A0Z]	[24]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Tramadol and ITI-007.	Insomnia [7A00-7A0Z]	[24]
Zolpidem	DMWOSKJ	Major	Additive CNS depression effects by the combination of Tramadol and Zolpidem.	Insomnia [7A00-7A0Z]	[24]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Tramadol and Quazepam.	Insomnia [7A00-7A0Z]	[24]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Tramadol and Estazolam.	Insomnia [7A00-7A0Z]	[24]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Tramadol and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[22]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Phenolphthalein.	Irritable bowel syndrome [DD91]	[22]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Tramadol and Clidinium.	Irritable bowel syndrome [DD91]	[19]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Tramadol and Dicyclomine.	Irritable bowel syndrome [DD91]	[19]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Tramadol and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[24]
Amifampridine	DMK08L3	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Amifampridine.	Lambert-Eaton syndrome [8C62]	[18]
Nelarabine	DMB6VEG	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Nelarabine.	Leukaemia [2A60-2B33]	[18]
Physostigmine	DM2N0TO	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[18]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Tramadol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[26]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Tramadol and Crizotinib.	Lung cancer [2C25]	[58]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Tramadol and Ceritinib.	Lung cancer [2C25]	[22]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Tramadol caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[59]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Tramadol and Osimertinib.	Lung cancer [2C25]	[60]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Tramadol and Selpercatinib.	Lung cancer [2C25]	[26]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Tramadol and Lumefantrine.	Malaria [1F40-1F45]	[61]
Meprobamate	DMHM93Y	Major	Additive CNS depression effects by the combination of Tramadol and Meprobamate.	Malaria [1F40-1F45]	[24]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Tramadol and Halofantrine.	Malaria [1F40-1F45]	[62]
Chloroquine	DMSI5CB	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Chloroquine.	Malaria [1F40-1F45]	[18]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Quinine.	Malaria [1F40-1F45]	[22]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Primaquine.	Malaria [1F40-1F45]	[22]
Mefloquine	DMWT905	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Mefloquine.	Malaria [1F40-1F45]	[18]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[26]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Tramadol and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[63]
Blinatumomab	DMGECIJ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Blinatumomab.	Mature B-cell lymphoma [2A85]	[18]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Tramadol and Vemurafenib.	Melanoma [2C30]	[22]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and LGX818.	Melanoma [2C30]	[64]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Tramadol and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[65]
Zolmitriptan	DM1IB4Q	Major	Additive serotonergic effects by the combination of Tramadol and Zolmitriptan.	Migraine [8A80]	[66]
Dihydroergotamine	DM5IKUF	Major	Additive serotonergic effects by the combination of Tramadol and Dihydroergotamine.	Migraine [8A80]	[66]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Tramadol and Almogran.	Migraine [8A80]	[66]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Tramadol and Frovatriptan.	Migraine [8A80]	[66]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Tramadol and Rizatriptan.	Migraine [8A80]	[66]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Tramadol and Naratriptan.	Migraine [8A80]	[66]
Sumatriptan	DMVYXR8	Major	Additive serotonergic effects by the combination of Tramadol and Sumatriptan.	Migraine [8A80]	[66]
Eletriptan	DMW649X	Major	Additive serotonergic effects by the combination of Tramadol and Eletriptan.	Migraine [8A80]	[66]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Tramadol and Lasmiditan.	Migraine [8A80]	[67]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Tramadol and Flibanserin.	Mood disorder [6A60-6E23]	[68]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Tramadol and Panobinostat.	Multiple myeloma [2A83]	[69]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Tramadol and Thalidomide.	Multiple myeloma [2A83]	[70]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Tramadol and Siponimod.	Multiple sclerosis [8A40]	[25]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Tramadol and Fingolimod.	Multiple sclerosis [8A40]	[22]
Dalfampridine	DMM0PDO	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Dalfampridine.	Multiple sclerosis [8A40]	[18]
Ozanimod	DMT6AM2	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Ozanimod.	Multiple sclerosis [8A40]	[71]
Carisoprodol	DMWR1JC	Major	Additive CNS depression effects by the combination of Tramadol and Carisoprodol.	Musculoskeletal disorder [FA00-FC0Z]	[24]
Neostigmine	DM6T2J3	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Neostigmine.	Myasthenia gravis [8C6Y]	[18]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Romidepsin.	Mycosis fungoides [2B01]	[22]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Tramadol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[26]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Tramadol and Nilotinib.	Myeloproliferative neoplasm [2A20]	[22]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Tramadol caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[72]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Dasatinib.	Myeloproliferative neoplasm [2A20]	[73]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Tramadol due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[74]
Dextroamphetamine	DMMIHVP	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Dextroamphetamine.	Narcolepsy [7A20]	[18]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Tramadol and Droperidol.	Nausea/vomiting [MD90]	[22]
Prochlorperazine	DM53SRA	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Prochlorperazine.	Nausea/vomiting [MD90]	[18]
Promethazine	DM6I5GR	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Promethazine.	Nausea/vomiting [MD90]	[18]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Tramadol caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[75]
Palonosetron	DMBHMOX	Major	Additive serotonergic effects by the combination of Tramadol and Palonosetron.	Nausea/vomiting [MD90]	[22]
Metoclopramide	DMFA5MY	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Metoclopramide.	Nausea/vomiting [MD90]	[18]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Tramadol and Granisetron.	Nausea/vomiting [MD90]	[22]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Tramadol and Dolasetron.	Nausea/vomiting [MD90]	[22]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Tramadol and Ondansetron.	Nausea/vomiting [MD90]	[22]
Thiethylperazine	DMU3IET	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Thiethylperazine.	Nausea/vomiting [MD90]	[18]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Bupropion.	Nicotine use disorder [6C4A]	[18]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Entrectinib.	Non-small cell lung cancer [2C25]	[25]
Phendimetrazine	DM6TS1N	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Phendimetrazine.	Obesity [5B80-5B81]	[18]
Amfepramone	DM9YSNQ	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Amfepramone.	Obesity [5B80-5B81]	[18]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Tramadol and Sibutramine.	Obesity [5B80-5B81]	[33]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Tramadol and Lorcaserin.	Obesity [5B80-5B81]	[76]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Tramadol and Dexfenfluramine.	Obesity [5B80-5B81]	[33]
Phenylpropanolamine	DMTFK3O	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Phenylpropanolamine.	Obesity [5B80-5B81]	[18]
Mazindol	DMZ36RN	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Mazindol.	Obesity [5B80-5B81]	[18]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Tramadol and Levomethadyl Acetate.	Opioid use disorder [6C43]	[26]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Tramadol and Lofexidine.	Opioid use disorder [6C43]	[22]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Tramadol and Apraclonidine.	Optic nerve disorder [9C40]	[50]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Rucaparib.	Ovarian cancer [2C73]	[22]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Triclabendazole.	Parasitic worm infestation [1F90]	[22]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Tramadol and Safinamide.	Parkinsonism [8A00]	[33]
Rasagiline	DM3WKQ4	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Rasagiline.	Parkinsonism [8A00]	[33]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Tramadol and Pimavanserin.	Parkinsonism [8A00]	[24]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Tramadol and Orphenadrine.	Parkinsonism [8A00]	[24]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Apomorphine.	Parkinsonism [8A00]	[22]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tramadol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[77]
Lindane	DMB8CNL	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Lindane.	Pediculosis [1G00]	[18]
Methylscopolamine	DM5VWOB	Moderate	Additive antimotility effects by the combination of Tramadol and Methylscopolamine.	Peptic ulcer [DA61]	[19]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Famotidine.	Peptic ulcer [DA61]	[25]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Tramadol and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[78]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Tramadol and Lefamulin.	Pneumonia [CA40]	[79]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Ritodrine.	Preterm labour/delivery [JB00]	[31]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Degarelix.	Prostate cancer [2C82]	[26]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and ABIRATERONE.	Prostate cancer [2C82]	[25]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Nilutamide.	Prostate cancer [2C82]	[26]
Enzalutamide	DMGL19D	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Enzalutamide.	Prostate cancer [2C82]	[18]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Flutamide.	Prostate cancer [2C82]	[26]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Relugolix.	Prostate cancer [2C82]	[26]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Bicalutamide.	Prostate cancer [2C82]	[26]
Alfuzosin	DMZVMKF	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Alfuzosin.	Prostate hyperplasia [GA90]	[22]
Levomepromazine	DMIKFEL	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[18]
Fluphenazine	DMIT8LX	Major	Additive CNS depression effects by the combination of Tramadol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[80]
Triflupromazine	DMKFQJP	Major	Additive CNS depression effects by the combination of Tramadol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[24]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Sorafenib.	Renal cell carcinoma [2C90]	[22]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Tramadol and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[34]
Doxapram	DMCYANK	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Doxapram.	Respiratory system disease [CB40-CB7Z]	[18]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Tramadol caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[81]
Oxamniquine	DM2QDX1	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Oxamniquine.	Schistosomiasis [1F86]	[18]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Tramadol and Quetiapine.	Schizophrenia [6A20]	[22]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Tramadol and Mesoridazine.	Schizophrenia [6A20]	[22]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Tramadol and Thioridazine.	Schizophrenia [6A20]	[22]
Aripiprazole	DM3NUMH	Major	Increased risk of prolong QT interval by the combination of Tramadol and Aripiprazole.	Schizophrenia [6A20]	[25]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Tramadol and Iloperidone.	Schizophrenia [6A20]	[22]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Tramadol and Paliperidone.	Schizophrenia [6A20]	[24]
Loxapine	DM8AI9U	Major	Additive CNS depression effects by the combination of Tramadol and Loxapine.	Schizophrenia [6A20]	[80]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Tramadol and Haloperidol.	Schizophrenia [6A20]	[22]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Tramadol and Perphenazine.	Schizophrenia [6A20]	[24]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Tramadol and Molindone.	Schizophrenia [6A20]	[24]
Chlorpromazine	DMBGZI3	Major	Additive CNS depression effects by the combination of Tramadol and Chlorpromazine.	Schizophrenia [6A20]	[80]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Tramadol and Thiothixene.	Schizophrenia [6A20]	[80]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Tramadol and Clozapine.	Schizophrenia [6A20]	[22]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Tramadol and Trifluoperazine.	Schizophrenia [6A20]	[24]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Tramadol and Ziprasidone.	Schizophrenia [6A20]	[22]
Risperidone	DMN6DXL	Major	Additive CNS depression effects by the combination of Tramadol and Risperidone.	Schizophrenia [6A20]	[24]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Tramadol and Amisulpride.	Schizophrenia [6A20]	[82]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Tramadol and Asenapine.	Schizophrenia [6A20]	[22]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Tramadol and Pimozide.	Schizophrenia [6A20]	[26]
Fentanyl	DM8WAHT	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Fentanyl.	Sensation disturbance [MB40]	[18]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Tramadol and Sufentanil.	Sensation disturbance [MB40]	[18]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Vardenafil.	Sexual dysfunction [HA00-HA01]	[22]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Tramadol and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[22]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Tramadol and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[22]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Pitolisant.	Somnolence [MG42]	[22]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[22]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Tramadol and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[22]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Tramadol and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[22]
Zithromax	DMN4H2O	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Zithromax.	Syphilis [1A61-1A6Z]	[22]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Tramadol and Anagrelide.	Thrombocytosis [3B63]	[22]
Brilinta	DMBR01X	Moderate	Altered absorption of Tramadol due to GI dynamics variation caused by Brilinta.	Thrombosis [DB61-GB90]	[74]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Tramadol due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[74]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Lenvatinib.	Thyroid cancer [2D10]	[22]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Tramadol and Cabozantinib.	Thyroid cancer [2D10]	[26]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Tramadol and Papaverine.	Tonus and reflex abnormality [MB47]	[83]
Tizanidine	DMR2IQ4	Major	Additive CNS depression effects by the combination of Tramadol and Tizanidine.	Tonus and reflex abnormality [MB47]	[24]
Trospium	DMX6RTG	Moderate	Additive antimotility effects by the combination of Tramadol and Trospium.	Tonus and reflex abnormality [MB47]	[19]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Tacrolimus.	Transplant rejection [NE84]	[22]
Atropine	DMEN6X7	Moderate	Additive antimotility effects by the combination of Tramadol and Atropine.	Unspecific substance harmful effect [NE6Z]	[19]
Cinoxacin	DM4EWNS	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Cinoxacin.	Urinary tract infection [GC08]	[18]
Nalidixic acid	DMRM0JV	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Nalidixic acid.	Urinary tract infection [GC08]	[18]
Enoxacin	DMYTE6L	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Enoxacin.	Urinary tract infection [GC08]	[18]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[22]
Methdilazine	DMAUHQX	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Tramadol and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[84]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Tramadol and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[22]
Mexiletine	DMCTE9R	Major	Increased risk of lowers seizure threshold by the combination of Tramadol and Mexiletine.	Ventricular tachyarrhythmia [BC71]	[18]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Tramadol and Procainamide.	Ventricular tachyarrhythmia [BC71]	[22]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Propafenone.	Ventricular tachyarrhythmia [BC71]	[22]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Tramadol and Flecainide.	Ventricular tachyarrhythmia [BC71]	[22]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Tramadol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[22]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aspartame	E00402	134601	Flavoring agent
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sucrose stearate	E00502	9898327	Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dibutyl sebacate	E00160	7986	Plasticizing agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tramadol 50 mg tablet	50 mg	Oral Tablet	Oral
Tramadol 50 mg tablet	50 mg	Disintegrating Tablet	Oral
Tramadol 200 mg capsule	200 mg	24 HR Extended Release Oral Capsule	Oral
Tramadol 300 mg capsule	300 mg	24 HR Extended Release Oral Capsule	Oral
Tramadol 100 mg capsule	100 mg	24 HR Extended Release Oral Capsule	Oral
Tramadol 100 mg tablet	100 mg	24 HR Extended Release Oral Tablet	Oral
Tramadol 200 mg tablet	200 mg	24 HR Extended Release Oral Tablet	Oral
Tramadol 200 mg tablet	200 mg	24 HR Extended Release Tablet	Oral
Tramadol 100 mg tablet	100 mg	24 HR Extended Release Tablet	Oral
Tramadol 300 mg tablet	300 mg	24 HR Extended Release Tablet	Oral
Tramadol 150 mg capsule	150 mg	24 HR Extended Release Capsule	Oral
Tramadol 150 mg capsule	150 mg	24 HR Extended Release Oral Capsule	Oral
Tramadol 100 mg tablet	100 mg	Matrix Delivery 24 HR Extended Release Oral Tablet	Oral
Tramadol 200 mg tablet	200 mg	Matrix Delivery 24 HR Extended Release Oral Tablet	Oral
Tramadol 300 mg tablet	300 mg	24 HR Extended Release Oral Tablet	Oral
Tramadol 300 mg tablet	300 mg	Matrix Delivery 24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Tramadol FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8286).
• [3] BDDCS applied to over 900 drugs
• [4] FDA Approved Drug Products: Ultram (tramadol hydrochloride) oral tablets
• [5] Vazzana M, Andreani T, Fangueiro J, Faggio C, Silva C, Santini A, Garcia ML, Silva AM, Souto EB: Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8. doi: 10.1016/j.biopha.2015.01.022. Epub 2015 Feb 7.
• [6] Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician. 2015 Jul-Aug;18(4):395-400.
• [7] Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [10] Barakat A: Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019 May;33(5):481-501. doi: 10.1007/s40263-019-00623-5.
• [11] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [12] Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8.
• [13] Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
• [14] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [15] Comparative study of the neurotoxicological effects of tramadol and tapentadol in SH-SY5Y cells. Toxicology. 2016 Jun 1;359-360:1-10. doi: 10.1016/j.tox.2016.06.010. Epub 2016 Jun 15.
• [16] Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Toxicol In Vitro. 2018 Mar;47:63-71.
• [17] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [18] Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
• [19] Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
• [20] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
• [21] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [22] Canadian Pharmacists Association.
• [23] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [24] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [25] Cerner Multum, Inc. "Australian Product Information.".
• [26] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [27] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [28] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [29] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [30] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [31] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [32] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [33] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [34] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [35] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [36] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [37] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
• [38] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [39] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [40] Pisani F, Spina E, Oteri G "Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice." Epilepsia 40(Suppl 10) (1999): S48-56. [PMID: 10609604]
• [41] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [42] Alfaro CL, Lam YWF, Simpson J, Ereshefsky L "CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline." J Clin Psychopharmacol 19 (1999): 155-63. [PMID: 10211917]
• [43] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
• [44] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
• [45] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [46] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [47] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [48] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [49] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [50] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [51] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [52] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [53] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [54] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [55] Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
• [56] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [57] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [58] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [59] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [60] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [61] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [62] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [63] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [64] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [65] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [66] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [67] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [68] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [69] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [70] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [71] Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23. [PMID: 7854515]
• [72] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [73] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [74] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [75] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [76] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [77] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [78] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [79] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [80] Cerner Multum, Inc. "Canadian Product Information.".
• [81] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [82] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [83] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [84] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.